RADNOR, Pa., July 13, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today outlined the potential benefits that the Generating Antibiotics Incentives Now (GAIN) Act will have for PolyMedix.
